Compare Charles River Laboratories Intl. Inc (CRL) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Vanguard Total International Stock Index Fund ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $297.28 (market cap $14.34B), while Vanguard Total International Stock Index Fund ETF trades at $84.82 (market cap $665.70B). The key difference: Vanguard Total International Stock Index Fund ETF is far larger — about 46.4× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Vanguard Total International Stock Index Fund ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Vanguard Total International Stock Index Fund ETF for 55 Days on average.
| CRL | VXUS | |
|---|---|---|
Market Cap | $14.34B | $665.70B |
Volume | 1,242,136 | 4,890,695 |
Sector | Health | Sector/Thematic |
52-Week High | $310.77 | $88.41 |
52-Week Low | $149.93 | $72.17 |
Typical Hold Time | 33 Days | 55 Days |
Enterprise Value | $17.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298.00, down 2.28% on the day, but maintains a bullish technical outlook with strong analyst support. The stock has consistently beaten earnings expectations in recent quarters, though profitability metrics show challenges with negative net income margins and ROE. Recent investor day presentations highlighted a refreshed growth strategy targeting 5-7% organic revenue growth and $300 million in cost savings by 2030, providing fundamental catalysts.
While CRL faces profitability headwinds and premium valuation multiples, strong analyst consensus (73% buy ratings) and a $305.50 price target suggest upside potential. Key risks include execution on margin improvement targets and ongoing cost volatility in non-human primate services. The combination of technical strength, strategic initiatives, and Wall Street support creates a favorable risk-reward profile for growth-oriented investors.
VXUS, the Vanguard Total International Stock ETF, is trading at $84.78, down 1.19% on the day, with a bearish technical signal driven by moving averages. The ETF provides diversified exposure to international developed and emerging markets outside the U.S. Recent news highlights its role in portfolio diversification and long-term growth potential, with several financial firms increasing their positions in Q2 2026.
The outlook for VXUS hinges on international market performance relative to the U.S., offering a hedge against domestic downturns. Key risks include currency fluctuations, geopolitical tensions, and the ETF's inability to reclaim foreign tax credits in IRAs. Its low-cost, broad diversification presents a strategic opportunity for long-term investors seeking global equity exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
